Literature DB >> 16195878

Interpreting cell cycle effects of drugs: the case of melphalan.

Monica Lupi1, Paolo Cappella, Giada Matera, Claudia Natoli, Paolo Ubezio.   

Abstract

Multiple effects usually occur in the cell cycle, during and after the exposure to a drug, while treated cells flowing through the cycle encounter G1, S and G2M checkpoints. We developed a simulation tool connecting the microscopic level of the cellular response in G1, S and G2M with the experimental data of growth inhibition and flow cytometry. We found that multiple-often not intuitive-combinations of cytostatic and cytotoxic effects can be in keeping with the observations. This multiplicity of interpretation can be strongly reduced by considering together data with different methods, ideally reaching a reconstruction of the underlying cell cycle perturbations. Here, we propose an experimental plan including a time course of DNA flow cytometry and absolute cell count measurements with several drug concentrations and a limited number of flow cytometric DNA-Bromodeoxyuridine and TUNEL analyses, coupled with computer simulation. We showed its use in the attempt to define the complete time course of the effects of melphalan on three cancer cell lines. After drug treatment, each subset of cells experienced blocks and lethality in all phases of the cell cycle, but the dynamics was different, the differences being strongly dose-dependent. Our approach allows a better appreciation of the complexity of the cell cycle phenomena associated with drug treatment. It is expected that such level of understanding of the time- and dose-dependence of the cytostatic and cytotoxic effects of a drug might support rational therapeutic design.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16195878     DOI: 10.1007/s00280-005-0044-1

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

1.  Enhanced cell cycle perturbation and apoptosis mediate the synergistic effects of ST1926 and ATRA in neuroblastoma preclinical models.

Authors:  Angela Maria Di Francesco; Paolo Ubezio; Anna Rita Torella; Daniela Meco; Filomena Pierri; Giuseppe Barone; Gabriella Cusano; Claudio Pisano; Maurizio D'Incalci; Riccardo Riccardi
Journal:  Invest New Drugs       Date:  2011-06-03       Impact factor: 3.850

2.  Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach.

Authors:  M Tavecchio; C Natoli; P Ubezio; E Erba; M D'Incalci
Journal:  Cell Prolif       Date:  2007-12       Impact factor: 6.831

3.  Fenofibrate induces G0/G1 phase arrest by modulating the PPARα/FoxO1/p27 kip pathway in human glioblastoma cells.

Authors:  Dong-feng Han; Jun-xia Zhang; Wen-jin Wei; Tao Tao; Qi Hu; Ying-yi Wang; Xie-feng Wang; Ning Liu; Yong-ping You
Journal:  Tumour Biol       Date:  2015-01-08

4.  Beyond The T/C Ratio: Old And New Anticancer Activity Scores In Vivo.

Authors:  Paolo Ubezio
Journal:  Cancer Manag Res       Date:  2019-09-19       Impact factor: 3.989

5.  relocating job wise? A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor.

Authors:  Peter Hinow; Shizhen Emily Wang; Carlos L Arteaga; Glenn F Webb
Journal:  Theor Biol Med Model       Date:  2007-04-03       Impact factor: 2.432

6.  Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer.

Authors:  Paolo Ubezio; Francesca Falcetta; Laura Carrassa; Monica Lupi
Journal:  Oncotarget       Date:  2016-03-29

7.  Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.

Authors:  Valentina Restelli; Rosaria Chilà; Monica Lupi; Andrea Rinaldi; Ivo Kwee; Francesco Bertoni; Giovanna Damia; Laura Carrassa
Journal:  Oncotarget       Date:  2015-11-10

8.  MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents.

Authors:  M Y Shah; E Martinez-Garcia; J M Phillip; A B Chambliss; R Popovic; T Ezponda; E C Small; C Will; M P Phillip; P Neri; N J Bahlis; D Wirtz; J D Licht
Journal:  Oncogene       Date:  2016-04-25       Impact factor: 9.867

9.  Dynamic rendering of the heterogeneous cell response to anticancer treatments.

Authors:  Francesca Falcetta; Monica Lupi; Valentina Colombo; Paolo Ubezio
Journal:  PLoS Comput Biol       Date:  2013-10-17       Impact factor: 4.475

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.